Aslı BOLAYIR, Özlem KAYIM YILDIZ, Hatice BALABAN, Şeyda Figül GÖKÇE, Sanem NEMMEZİ KARACA, Ahmet Suat TOPAKTAŞ, Burhanettin ÇİĞDEM

Prevalence of multiple sclerosis in an urban population of Sivas province in Turkey

Background/aim: Multiple sclerosis (MS) is a common neurological disorder that can be a leading cause of nontraumatic disability inseveral countries. Recent reports have indicated a moderate to high risk of MS in European countries. In this study, we examined theprevalence of MS in a well-defined urban population of provincial center in Sivas Province in Turkey.Materials and methods: This study sampled all registered residents of urban areas of provincial center in Sivas Province in April 2017and 2018 January. All the included patients met the McDonald 2010 criteria. Medical records were reviewed, including all availablepreviously acquired magnetic resonance imaging data. All patients were subsequently subjected to neurologic examination to confirmthe MS diagnosis.Results: We identified 21 possible MS patients, with MS diagnosis confirmed in 19. The prevalence of MS was 288 per 100,000 inhabitants.Conclusion: For future studies, these high ratio results can be used in regional and national comparisons to determine cofactorscontributing to the high prevalence of MS in our region and can help health-decision makers to better plan healthcare policies toimprove neurological services and awareness about multifaceted clinical presentations of MS.

PDF

___

1. Luzzio C. (2018) Multiple sclerosis. [online] Emedicine. medscape.com. Available at: emedicine.medscape.com/ article/1146199-overview [Accessed 3 Aug. 2018].
2. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014; 83: 1022-1024.
3. Cristiano E, Patrucco L, Rojas JI. A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 2008; 15: 1273-1278.
4. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015; 5: e0036214.
5. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117-139.
6. Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013; 136: 3609-3617.
7. Sadovnick AD, Yee IM, Guimond C, Reis J, Dyment DA et al. Age of onset in concordant twins and other relative pairs with multiple sclerosis. Am J Epidemiol 2009; 170: 289-296.
8. Olek MJ. Differential diagnosis, clinical features, and prognosis of multiple sclerosis. In: Olek MJ, editor. Multiple Sclerosis Etiology, Diagnosis, and New Treatment Strategies. Totowa, NJ, USA: Humana Press; 2005. pp. 15-53.
9. Ashtari F, Shaygannejad V, Farajzadegan Z, Amin A. Does early-onset multiple sclerosis differ from adult-onset form in Iranian people. J Res Med Sci 2010; 15: 94-99.
10. Alroughani R, Ahmed SF, Behbahani R, Khan R, Thussu A et al. Increasing prevalence and incidence rates of multiple sclerosis in Kuwait. Mult Scler 2014; 20: 543-547.
11. Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua B et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler 2013; 19: 816-819.
12. Kalanie H, Gharagozli K, Kalanie AR. Multiple sclerosis: report on 200 cases from Iran. Mult Scler 2003; 9: 36-38.
13. Ha-Vinh P, Nauleau S, Clementz M, Régnard P, Sauze L et al. Geographic variations of multiple sclerosis prevalence in France: the latitude gradient is not uniform depending on the socioeconomic status of the studied population. Mult Scler J Exp Transl Clin 2016; 2: 2055217316631762.
14. Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin 2016; 34: 919-939.
15. Kotzamani D, Panou T, Mastorodemos V, Tzagournissakis M, Nikolakaki H et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012; 78: 1728-1735.
16. Spirin NN, Kachura DA, Kachura AN, Boĭko AN.Zh. The influence of environmental factors on the incidence and prevalence of multiple sclerosis. Nevrol Psikhiatr Im S S Korsakova 2003; 2: 111-113.
17. Kurtzke JF. Multiple sclerosis in time and space--geographic clues to cause. J Neurovirol 2000; 6: 134-140.
18. Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. London: Multiple Sclerosis International Federation; 2013. Available at: http://www.msif.org/about-ms/ publications-and-resources/. Accessed Aug 3, 2018.
19. Türk Börü Ü, Alp R, Sur H, Gül L. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiology 2006; 27: 17-21.
20. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
21. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol 2016; 172: 3-13.
22. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch Orofacial Sci 2006; 1: 9-14.
23. Akdemir N, Terzi M, Arslan N, Onar M. Prevalence of Multiple Sclerosis in the Middle Black Sea Region of Turkey and Demographic Characteristics of Patients. Nöro Psikiyatr Arş 2017; 54:11-14.
24. Türk Börü Ü, Taşdemir M, Güler N, Ayık ED, Kumaş A, Yıldırım S et al. Prevalence of multiple sclerosis: door-todoor survey in three rural areas of coastal Black Sea regions of Turkey. Neuroepidemiology 2011; 37: 231-235.
25. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277.
26. Tshala-Katumbay D, Mwanza JC, Rohlman DS, Maestre G, Oriá RB. A global perspective on the influence of environmental exposures on the nervous system. Nature 2015; 527: 187-192.
27. Alp R, Alp SI, Planci Y, Yapici Z, Turk Boru U. The prevalence of multiple sclerosis in the north caucasus region of Turkey: Door-to-door epidemiological field study. Nöro Psikiyatr Arş 2012; 49: 272-275.
28. Vassallo L, Elian M, Dean G. Multiple sclerosis in southern Europe. II: Prevalence in Malta in 1978. J Epidemiol Community Health 1979; 33: 111-113.
29. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010; 9: 387- 394.
30. Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio doctoralis. Neurol Sci 2000; 21: 383-403.
31. Sardu C, Cocco E, Mereu A, Massa R, Cuccu A,et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 2012; 7: e32487.
32. Candeliere-Merlicco A, Valero-Delgado F, Martínez-Vidal S, Lastres-Arias Mdel C et al. Prevalence of multiple sclerosis in Health District III, Murcia, Spain. Mult Scler Relat Disord 2016; 9: 31-35.
33. Granieri E, Casetta I, Govoni V, Tola MR, Marchi D et al. The increasing incidence and prevalence of MS in a Sardinian province. Neurology 2000; 55: 842-848.
34. Berg-Hansen P, Moen SM, Harbo HF, Celius EG. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 2014; 20: 1780-1782.
35. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O’Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014; 85: 76-84.
36. Svenningsson A, Salzer J, Vågberg M, Sundström P, Svenningsson A. Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden. Acta Neurol Scand 2015; 132: 389-394.
37. Höer A, Schiffhorst G, Zimmermann A, Fischaleck J, Gehrmann L et al. Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system. BMC Health Serv Res 2014; 14: 381.
38. El Adssi H, Debouverie M, Guillemin F; LORSEP Group. Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method. Mult Scler 2012; 18: 1244-1250.
39. Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B et al. Multiple sclerosis prevalence in Ireland relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 2011; 82: 317-322.
40. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR et al. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 2016; 86: 1014- 1021.
41. Visser EM, Wilde K, Wilson JF, Yong KK, Counsell CE. A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city. J Neurol Neurosurg Psychiatry 2012; 83: 719- 724.
42. Sumelahti ML, Tienari PJ, Wikstrom J, Palo J, Hakama M: Increasing prevalence of multiple sclerosis in Finland. Acta neurol Scand 2001; 103: 153-158.
43. Ahlgren C, Oden A, Lycke J: High nationwideprevalence of multiple sclerosis in Sweden.Mult Scler 2011; 17: 901-908.
44. Houzen H, Niino M, Hata D, Nakano F, Kikuchi S et al. Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 2008; 14: 887-892.
45. Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler 2011; 17: 1022-1027.
46. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61: 1373-1377.
47. Benito-Leon J: Multiple sclerosis: is prevalence rising and if so why? Neuroepidemiology 2011; 37: 236-237.
48. Alonso A, Hernán MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129-135.
49. Benito-León J. Are the prevalence and incidence of multiple sclerosis changing? Neuroepidemiology 2011; 36: 148-149.
50. Hirst C, Ingram G, Pickersgill T, Swingler R, Compston DA et al. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry 2009; 80: 386-391.
51. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532.
52. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
53. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012; 78: 1315-1322.
54. Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro 2015; 7: pii: 1759091414568185.
55. Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther 2018; 7: 59-85.
56. Sedaghat F, Jessri M, Behrooz M, Mirghotbi M, Rashidkhani B. Mediterranean diet adherence and risk of multiple sclerosis: a case-control study. Asia Pac J Clin Nutr 2016; 25: 377-384.